AstraZeneca Completes Phase 3 Trial for Hypertension Drug Acquired in $1.3 Billion CinCor Deal

AstraZeneca has announced that its experimental drug for uncontrolled or treatment-resistant hypertension has successfully completed a phase 3 clinical trial. The development comes two years after the pharmaceutical company acquired CinCor Pharma in a $1.3 billion deal, with the drug being the primary asset of that acquisition. AstraZeneca is now preparing to file for regulatory approval based on the trial results.

The phase 3 trial marks a significant milestone for the drug, which aims to address cases of high blood pressure that do not respond adequately to existing treatments. AstraZeneca’s acquisition of CinCor Pharma in 2023 was largely driven by this potential therapy, underscoring its strategic importance within the company’s portfolio. Details regarding the specific outcomes of the trial have not been disclosed, but clearing this stage positions AstraZeneca closer to bringing the medication to market pending regulatory review.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: July 14, 2025

Author

Mark Chiang